**Takeda’s Psoriasis Drug Zasocitinib Shows Promising Results in Trials**
Takeda Pharmaceutical Co. experienced its largest stock increase in seven months on Friday, following the announcement that its oral psoriasis treatment, zasocitinib, demonstrated safety and efficacy in late-stage clinical trials. This development marks a significant step forward in addressing the challenging skin condition, which currently has no cure.
In early trading in Tokyo, Takeda’s stock surged by as much as 4.3%, marking the most substantial intraday rise since May 13. The company reported that over half of the patients with moderate-to-severe plaque psoriasis experienced near-complete resolution of their symptoms, while approximately 30% achieved full clearance after 16 weeks of treatment, compared to those receiving a placebo or the existing treatment, apremilast. Takeda plans to submit the trial data to the U.S. Food and Drug Administration and other regulatory bodies starting in fiscal 2026.
Hidemaru Yamaguchi, an equities analyst at Citigroup Global Markets Japan Inc., commented on the results, stating, “This represents best-in-class data and leaves quite a positive impression. Expectations for the drug were not particularly high.”
If approved, zasocitinib would join a select group of oral treatments for psoriasis, a market traditionally dominated by topical ointments and injectable therapies. Notably, it would also be among the first drugs developed with the assistance of artificial intelligence, which played a crucial role in rapidly identifying zasocitinib from a large array of potential candidates, according to Jeb Keiper, CEO of Nimbus Therapeutics, the company that discovered the drug.
Takeda acquired zasocitinib, also known as TAK-279, from Nimbus in 2023 for an upfront payment of $4 billion, with additional milestone payments potentially reaching $2 billion. This therapy is part of Takeda’s strategy to mitigate anticipated sales declines following the expected generic competition for its leading ulcerative colitis drug, Entyvio. Yamaguchi estimates that zasocitinib could generate peak annual sales of ¥150 billion (approximately $964 million) and a per-share value of ¥750.
The global market for psoriasis treatments, valued at $27 billion in 2024, is projected to nearly double to $58 billion by 2032, according to research from Fortune Business Insights. Psoriasis is a chronic autoimmune condition affecting over 125 million people worldwide, characterized by itchy, scaly rashes.
**FAQ**
**What is zasocitinib and how does it work?**
Zasocitinib is an oral medication developed by Takeda Pharmaceutical Co. for the treatment of moderate-to-severe plaque psoriasis. It works by targeting specific pathways involved in the inflammatory process of psoriasis, leading to significant improvements in skin condition for many patients.